Base Therapeutics
PrivateLast Round
Series A
Extension
Sep 12, 2024
Total Funding Raised
$34.5M
Company Overview
Base Therapeutics operates in Healthcare & Life Sciences and is based in Shanghai. Its latest recorded funding round was a Series A Extension round in September 2024.
Base Therapeutics is a biotechnology company specializing in gene editing and cell-based therapies for the treatment of cancer and genetic diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting, Data as a Service
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Base Therapeutics Comparables
Compare Base Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| YolTech Therapeutics | 80% | |
| Beam Therapeutics | 78% | |
| Prime Medicine | 78% |
For institutional investors. Book with your work email.
Base Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A Extension | Sep 12, 2024 | ||||
| Series A | Jan 18, 2023 |
For institutional investors. Book with your work email.
Base Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| HighLight Capital | Series A |
| Gobi Partners | Seed |
| Spark Ventures | Series A |
| Baidu Ventures | Series A |
| Gobi Partners GBA | Series A Extension |
Market signals
Structured signals derived from secondary market and firmographic data.
- Oct 28, 2025
Collaborates with Synthego and KACTUS on base-editing technologies.
- Sep 12, 2024
Led by aef-greater-bay-area-fund with participation from Gobi Partners GBA.
For institutional investors. Book with your work email.
Base Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Base Therapeutics's valuation, stock price, and market status.
Is Base Therapeutics a public or private company?
Base Therapeutics is a private company.
What is the current stock price of Base Therapeutics?
Base Therapeutics is a private company, so its shares have no public market price. Caplight tracks Base Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Base Therapeutics worth (valuation)?
Valuation information for Base Therapeutics is not publicly available.
Can I buy Base Therapeutics stock?
Base Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Base Therapeutics's last funding round?
Base Therapeutics's most recent funding round was Series A Extension on September 12, 2024.
Who are the main investors in Base Therapeutics?
Key investors in Base Therapeutics include HighLight Capital, Gobi Partners, Spark Ventures, Baidu Ventures, Gobi Partners GBA.
Will Base Therapeutics IPO soon?
No public IPO plans have been announced for Base Therapeutics.
How can I track Base Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Base Therapeutics's shares on secondary markets.